Nanobiotix is transforming into a capital-light oncology platform focused on milestone and royalty revenues, centered on its JNJ-1900 program now led by Johnson & Johnson. JNJ-1900 aims to enhance radiotherapy across multiple solid tumors, with a potential $2.6 billion milestone structure and double-digit royalties. Recent financing and a planned equity raise in May 2026 extend Nanobiotix's cash runway through 2029, transferring much clinical and operational risk to J&J. While speculative, Nanobiotix offers upside if its radiotherapy platform gains broad adoption but faces risks including clinical trial outcomes, operational challenges, and dilution from fundraising.
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Bitcoin's recent price movements align with a historical cycle pattern suggesting it may have reached a low point, potentially signaling the start of a new bull market. Analysts project Bitcoin could hit $190,000 soon, with some traders like Peter Br...
Bitcoin (BTC) traded close to $85,580 as buying interest surpassed selling on Binance perpetual and Hyperliquid perpetual markets. Binance perpetual had $49.7 million in buy orders versus $45.7 million in sell orders, showing a $4 million net buying ...
Americas Gold and Silver (USAS) has taken full ownership of the high-grade Galena silver mine and acquired the Crescent mine to increase future production. Despite a weak second quarter at Galena, management targets 3.2–3.6 million ounces of silver o...
BTW surged 23.7% to $1.20, leading altcoin gains while Bitcoin remained stable around $85,583. This sharp rise highlights growing investor interest in specific altcoins despite a 3.3% drop in total crypto market cap and steady Bitcoin dominance at 59...
